Mankind Pharma Limited MANKIND.NS · Stock Open Mankind Pharma Limited in new tab
Mankind Pharma Limited Analysis (MANKIND.NS)
Is Mankind Pharma Limited a good investment? Mankind Pharma Limited (MANKIND.NS) is currently trading at 2483.00 INR. Market analysts have a consensus price target of 2675.37 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 50.00. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Mankind Pharma Limited is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is 70.82.
For income investors, Mankind Pharma Limited pays a dividend yield of 0.04%. With a payout ratio of 2%, the dividend appears sustainable.
Investor FAQ
Does Mankind Pharma Limited pay a dividend?
Yes, it pays an annual dividend of 1.00 INR (0.04% yield).
What asset class is Mankind Pharma Limited?
Mankind Pharma Limited is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 49.39.
Company Profile
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
| Year | Total Dividends |
|---|---|
| ▸2026 |
1.00 INR
|
| Aug. 31, 2026 (estimated) | 1.0000 |
| ▸2025 |
1.00 INR
|
| Aug. 30, 2025 | 1.0000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Mankind Pharma Limited | Aug 30, 2025 | Paid | 1.0 INR |
Community Discussion